- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Tailoring HS Treatment: The Path to Better Patient Outcomes
A panelist discusses how clinicians should systematically adopt evidence-based hidradenitis suppurativa (HS) guidelines while maintaining flexibility to tailor treatments to individual patient needs, severity levels, and comorbidities. This involves regular monitoring of updated recommendations, implementing standardized assessment tools, and considering patient-specific factors such as lifestyle, preferences, and treatment response history to optimize therapeutic outcomes through a personalized medicine approach.
EP: 1.Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa
EP: 2.Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity
EP: 3.Addressing Social Determinants of Health in Hidradenitis Suppurativa Care
EP: 4.Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa
EP: 5.Strategies for Equitable Access in Hidradenitis Suppurativa
EP: 6.Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes
EP: 7.Holistic Care for HS Patients: The Power of Multidisciplinary Models
EP: 8.The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes
EP: 9.Innovating HS Care: Applying Multidisciplinary Lessons to Diagnosis and Management
EP: 10.The Value Proposition: Justifying the Investment in HS Centers of Excellence
EP: 11.Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions
EP: 12.Navigating HS Management: The Patient Journey
EP: 13.Advancing HS Outcomes: Resource Prioritization and Success Measurement
EP: 14.Tailoring HS Treatment: The Path to Better Patient Outcomes
Video content above is prompted by the following:
- How can clinicians integrate evolving guidelines into practice to enhance patient outcomes?
- How can clinicians balance adherence to guidelines with the need for individualized patient care in HS treatment?
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More
